Tivic ClearUP Expands Target Market Offering to Include Individuals Who Are Sleep Deprived, Medication Restricted, and Athletes
15 6월 2023 - 10:00PM
Business Wire
Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health
tech company that develops and commercializes bioelectronic
medicine, announced today that the company is expanding its target
market for ClearUP to the vast population of consumers with allergy
and congestion-related issues who are deprived of sleep, exercise,
and concentration.
A recent Tivic study with over 2,000 representative consumers
conducted by Intellego Insights highlights patterns of the large
unmet market. The results of the study involved consumers over the
age of 18 experiencing inflammation-related symptoms related to
allergies, congestion, head pain, and sinus issues. Of the
consumers that participated in the study:
- 94% of these consumers use medication to treat their symptoms.
However, 58% of these try to avoid medication, if at all
possible.
- 91% of these consumers have sleep issues, such as trouble
sleeping and waking up often, snoring, and obstructive sleep
apnea.
- 69% of these consumers experience exercise-related nasal
issues, such as post-nasal drip after exercise or running, and are
unable to breathe comfortably through their nose during exercise or
exertion.
Congestion can have a significant impact on sleep quality and
exercise. When a person is congested, the nasal passages and
airways become narrowed, making it hard to breathe. When a person’s
breathing is compromised due to congestion, the body may also have
to work harder to get enough oxygen, which can cause the person to
feel tired, groggy, and have lower concentration.
Many consumers try to avoid medication due to cost, side
effects, and interaction with other medications. Labels of leading
medications to treat inflammation-related symptoms include
potential side effects of insomnia, heart palpitations,
restlessness, headache, and dizziness. Some professions, such as
first responders and medical professionals, also have restrictions
on their use of medication that can cause drowsiness.
- 60% of consumers in the Tivic study were concerned about the
ongoing cost of medication. 37% of these consumers indicated they
cannot tolerate the side effects of medication.
- 18% took medication (such as high blood pressure medication)
that limits what other medication they can take for treating other
symptoms. 12% of these consumers indicated medication
dependence.
“Many of my patients don’t want to take medication due to
ongoing cost and side effects of continued medication use,
including nose bleeds,” says Dr. Adam Spiess, a board-certified
ENT. “I recommend they try the FDA-approved Tivic ClearUP, and I
have seen approximately an 80% success rate. My patients tell me
they are grateful that I am using cutting-edge technology to best
meet their needs.”
Tivic’s data from two previously conducted clinical trials
demonstrated the benefits of ClearUP including significant
improvements in sleep health, breathing during sleep, nose
breathing, and concentration for allergy and congestion sufferers.
The analysis also indicated an improvement in productivity and
concentration and a reduction in difficulty falling asleep, waking
up at night, fatigue, and irritability.
About Tivic Tivic is a commercial health tech company
advancing the field of bioelectronic medicine. Tivic’s patented
technology platform leverages stimulation on the trigeminal,
sympathetic, and vagus nerve structures. Tivic’s non-invasive and
targeted approach to the treatment of inflammatory chronic health
conditions gives consumers and providers drug-free therapeutic
solutions with high safety profiles, low risk, and broad
applications. Tivic’s first commercial product ClearUP is an FDA
approved, award-winning, handheld bioelectronic sinus device.
ClearUP is clinically proven, doctor-recommended, and is available
through online retailers and commercial distributors. For more
information visit http://tivichealth.com @TivicHealth
Forward-Looking Statements This press release may contain
“forward-looking statements” that are subject to substantial risks
and uncertainties. All statements, other than statements of
historical fact, contained in this press release are
forward-looking statements. Forward-looking statements contained in
this press release may be identified by the use of words such as
“anticipate,” “believe,” “contemplate,” “could,” “estimate,”
“expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,”
“predict,” “project,” “target,” “aim,” “should,” “will,” “would,”
or the negative of these words or other similar expressions,
although not all forward-looking statements contain these words.
Forward-looking statements are based on Tivic Health Systems,
Inc.’s current expectations and are subject to inherent
uncertainties, risks, and assumptions that are difficult to
predict. Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
Actual results could differ materially from those contained in any
forward-looking statement as a result of various factors,
including, without limitation: clinical trial results; market and
other conditions; supply chain constraints; macroeconomic factors,
including inflation; and unexpected costs, charges or expenses that
reduce Tivic’s capital resources. Given these risks and
uncertainties, you are cautioned not to place undue reliance on
such forward-looking statements. For a discussion of other risks
and uncertainties, and other important factors, any of which could
cause Tivic’s actual results to differ from those contained in the
forward-looking statements, see Tivic’s filings with the SEC,
including its Annual Report on Form 10-K for the year ended
December 31, 2022, filed with the SEC on March 31, 2023, under the
heading “Risk Factors”; as well as the company’s subsequent filings
with the SEC. Forward-looking statements contained in this press
release are made as of this date, and Tivic Health Systems, Inc.
undertakes no duty to update such information except as required by
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230615559309/en/
Media Contact: Kayleigh Westerfield 949-632-3439
Kayleigh.Westerfield@tivichealth.com Investor Contact:
Hanover International, Inc. ir@tivichealth.com
Tivic Health Systems (NASDAQ:TIVC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Tivic Health Systems (NASDAQ:TIVC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024